KDR and neoplasm: In line with previous results obtained with combined inhibition of VEGFR/PDGFR/FGFR either with BIBF 1120 (Nintedanib), our results confirm that Nintedanib inhibits the growth of LS174T xenografts and blocks tumor angiogenesis.